Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-11-28
2003-06-10
Bui, Phuong T. (Department: 1838)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S185100, C435S006120, C435S069100, C435S070100, C435S252300, C435S320100, C514S04400A, C530S350000
Reexamination Certificate
active
06576751
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to the identification and cloning of two FADD-like anti-apoptotic molecules that regulate Fas/TNFR1- or UV-induced apoptosis, to methods of using the same, and to compositions for and methods of making the same and to methods of making and using the same.
BACKGROUND OF THE INVENTION
Apoptotic cell death is essential for normal development and maintenance of normal tissue size homeostasis in multicellular organisms. There is growing evidence that dysregulation of apoptosis may lead to several human diseases including cancer and degenerative neuronal diseases such as Alzheimer's and Parkinson's diseases.
Several members of the caspase family of proteases (Alnemri, E. S. et al. 1996 Cell 87, 171, which is incorporated herein by reference) have been implicated as key regulators of programmed cell death or apoptosis (Alnemri, E. S. 1997 J. Cell. Biochem. 64, 33-42 and Henkart, P. A. 1996 Immunity 4, 195-201 which are incorporated herein be reference). The pro-apoptotic caspases can be divided into two groups: those with a large prodomain such as ICH-1 (caspase-2), Mch4 (caspase-10), Mch5/MACH/FLICE (caspase-8) and Mch6/ICE-Lap-6 (caspase-9) and those with a small prodomain such as CPP32/YAMA/Apopain (caspase-3), Mch2 (caspase-6) and Mch3/ICE-Lap-3 (caspase-7). Caspases with large prodomains are probably the most upstream caspases. They are recruited by several death-signaling receptors that belong to the TNFR family, through interactions of their prodomain with the receptor-interacting adaptor molecules FADD/Mort1 or CRADD/RAIDD. For example, the prodomains of Mch4 and Mch5 contain two tandem regions that show significant homology with the N-terminal death effector domain (DED) of FADD. Engagement of Fas/TNFR1 results in recruitment of FADD to the receptor complex, which presumably triggers activation of the caspase apoptotic pathway through interaction of its DED with the corresponding motifs in the prodomain of Mch5 and probably Mch4. CRADD presumably functions like FADD by recruiting ICH-1 to the Fas/TNFR1 complex, through interaction of its N-terminal domain with the corresponding motif in the prodomain of ICH-1. Thus, the prodomains of caspases function to physically link the death receptors to the downstream caspase activation pathway.
There is a need to identify proteins that regulate apoptosis. There is a need for isolated FADD-like anti-apoptotic molecules that regulate Fas/TNFR1- or UV-induced apoptosis, and for compositions and methods of producing and isolating FADD-like anti-apoptotic molecules that regulate Fas/TNFR1- or UV-induced apoptosis. There is a need to isolated proteins that are FADD-like anti-apoptotic molecules that regulate Fas/TNFR1- or UV-induced apoptosis. There is a need to isolated nucleic acid molecules that encode FADD-like anti-apoptotic molecules that regulate Fas/TNFR1- or UV-induced apoptosis. There is a need for compounds which inhibit activity of FADD-like anti-apoptotic molecules that regulate Fas/TNFR1- or UV-induced apoptosis. There is a need for kits and methods of identifying such compounds.
SUMMARY OF THE INVENTION
The invention relates to substantially pure proteins that have amino acid sequences shown in SEQ ID NO:2 or SEQ ID NO:4.
The invention relates to pharmaceutical compositions comprising a protein that has the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 in combination with a pharmaceutically acceptable carrier.
The invention relates to isolated nucleic acid molecules that comprise nucleic acid sequences that encode a protein that has an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4.
The invention relates to pharmaceutical compositions that comprise nucleic acid molecule that comprise nucleic acid sequences that encode a protein that has an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 in combination with a pharmaceutically acceptable carrier.
The invention relates to isolated nucleic acid molecules that consist of SEQ ID NO:1 or SEQ ID NO:3 or a fragment thereof having at least 5 nucleotides.
The invention relates to a recombinant expression vector comprising the nucleic acid molecule that has a nucleotide sequence that comprises SEQ ID NO:1 or SEQ ID NO:3.
The invention relates to a host cell comprising a recombinant expression vector comprising the nucleic acid molecule that has a nucleotide sequence that comprises SEQ ID NO:1 or SEQ ID NO:3.
The invention relates to an oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 5 nucleotides of SEQ ID NO:1 or SEQ ID NO:3.
The invention relates to isolated antibodies that bind to an epitope on SEQ ID NO:2 and/or SEQ ID NO:4.
The invention relates to methods of identifying substrates, activators or inhibitors of FLAME-1 and/or FLAME-2.
The invention relates to methods of inhibiting expression of FLAME-1 and/or FLAME-2 by contacting cells that express FLAME-1 and/or FLAME-2 with a nucleic acid molecule that comprises an antisense nucleotide sequence that prevents transcription of PLAME-1 and/or FLAME-2 gene sequences or translation of FLAME-1 and/or FLAME-2 mRNA.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5108921 (1992-04-01), Denny et al.
patent: 6037461 (2000-03-01), Alnemri
patent: 6063760 (2000-05-01), Alnemri
W. French Anderson, Nature, vol. 392, Supp., Apr. 30, 1998 p. 25-30.*
Ahmad, et al., “CRADD, a Novel Human Apoptotic Adaptor Molecule for Caspase-2, and FasL/ Tumor Necrosis Factor Receptor-interacting Protein RIP1”, Cancer Res.,1997, 57, 615-619.
Alnemri, et al., “Human ICE/CED-3 Protease Nomenclature”,Cell, 1996, 87, 171.
Alnemri, “Mammalian Cell Death Proteases: A Family of Highly Conserved Aspartate Specific Cysteine Proteases”,J. Cell. Biol., 1997, 64, 33-42.
Arad, et al., “Use of reconstituted Sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA: inhibition of protein synthesis in interferon-treated cells”,Biochim. Biophys. Acta, 1986, 859, 88-94.
Bertin, et al., “Apoptotic Suppression by Baculovirus P35 Involves Cleavage by and Inhibition of a Virus-Induced CED-3/ICE-Like Protease”,J. Virol., 1996, 70, 6251-6259.
Boldin, et al., “Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death”,Cell, 1996, 85, 803-815.
Bullrich, et al., “Chromosomal Mapping of Members of the cdc2 Family of Protein Kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk Inhibitor, p27Kipl, to Regions Involved in Human Cancer”,Cancer Research, 1995, 55, 1199-1205.
Capecchi, M.R., “Altering the Genome by Homologous Recombination”,Science, 1989, 244, 1288-1292.
Fernandes-Alnemri, et al., “In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains”,Proc. Natl. Acad. Sci. USA, 1996, 93, 7464-7469.
Fernandes-Alnemri, et al., “CPP32, a Novel Human Apoptotic Protein with Homology to Caenorhabditis elegans Cell Death Protein Ced-3 and Mammalian Interleukin-1&bgr;-converting Enzyme”,J. Biol. Chem., 1994, 269, 30761-30764.
Henkart, P.A., “ICE Family Proteases: Mediator of All Apoptotic Cell Death”,Immunity, 1996, 4, 195-201.
Li, et al., “Mice Deficient in IL-1&bgr;-Converting Enzyme Are Defective in Production of Mature IL-1&bgr;and Resistant to Endotoxic Shock”,Cell, 1995, 80, 401-411.
Lu, et al., “UV irradiation-induced apoptosis leads to activation of a 36-kDa myelin basic protein kinase in HL-60 cells”,Proc. Natl. Acad. Sci. USA, 1996, 93, 8977-8982.
Muzio, et al., “FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex”,Cell, 1996, 85, 817-827.
Nagata, S., “Apoptosis by Death Factor”,Cell, 1997, 88, 355-365.
Nagata, S., “Fas-Mediated Apoptosis”,Adv. Exp. Med. Biol., 1996, 406, 119-124.
Nagata, S. And Golstein, P., “The Fas Death Factor”,Science, 1995, 267, 1449-1456.
Nagata, S., “Fas and Fas Ligand: A Death Factor and Its Receptor”,Adv. Immunol., 1994, 57, 129-144.
Rosette, C. And Kar
Bui Phuong T.
Thomas Jefferson University
Woodcock & Washburn LLP
LandOfFree
FADD-like anti-apoptotic molecules, methods of using the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with FADD-like anti-apoptotic molecules, methods of using the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FADD-like anti-apoptotic molecules, methods of using the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3162657